Chair, Department of Investigational Cancer Therapeutics
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Dr Meric-Bernstam is a surgeon-scientist, with a surgical oncology practice focused on breast cancer. She is the Chair of the Department of Investigational Cancer Therapeutics (a Phase I Program) at The University of Texas MD Anderson Cancer Center), one of the largest Phase I programs in the world. She is the Medical Director of the MD Anderson Precision Oncology Decision Support program, PI of the Texas EXperimental Cancer Therapeutics Network, and leads MD Anderson’s Cancer Center Support Grant Developmental Therapeutics Program. She is a clinical trialist with 26 ongoing clinical trials and has extensive experience in novel therapeutics, including targeted therapies, antibody-drug conjugates, as well as correlative studies. She leads a basic and translational research program centered around cell signaling, biomarker discovery, and molecular therapeutics, with specific focus on modeling precision oncology in patient-derived models. She leads multi-institutional bench to bedside translation efforts including the NCI ComboMATCH precision medicine trial. She is also board certified in clinical informatics and site director for the University of Texas Clinical Informatics Fellowship Program. She is committed to training of surgeon-scientists and co-leads the MD Anderson Cancer Center T32 Program “Training Academic Surgical Oncologists”.
James Ewing Featured Lecture: Bench to Bedside Translation Through Team Science
Thursday, March 21, 2024
8:30am – 9:00am ET